Gastrointestinal Stromal Tumors
Treatment
Surgery is the standard treatment for primary resectable GIST. However, surgical resection is seldom curative, and by 5 years after complete removal of their tumor, half of patients having undergone such cancer treatments treated have relapsed.
Imatinib is the first-line treatment in patients with metastatic or unresectable GIST. It has resulted in durable objective response or stable disease in approximately 85% of patients with advanced GIST and is well tolerated.
‹ previous section | next section ›
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
PATIENT STORIES
"My sister died of breast cancer years ago. I'm a cancer survivor-because the battle is a lot different today."
- Carol Lundin
RESEARCH INNOVATION
Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.